Trial Profile
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide/dexamethasone-containing regimens
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Chemotherapy-induced damage; Neutropenia
- Focus Therapeutic Use
- 16 Nov 2018 New trial record